Agilon Health Adjusts To Recovery Phase, Analyst Is Cautious On Near-Term Fundamentals
1. AGL's EPS of $(0.26) missed estimates but revenue met expectations. 2. Analyst estimates indicate AGL's recovery will extend into 2025. 3. FY25 revenue estimate adjusted downwards to $5.926 billion. 4. FY26 revenue estimate also revised down to $6.594 billion. 5. AGL shares are currently down 0.48% at $4.18.